Legend Biotech Corporation

LEGN · Nasdaq · United States

Share price · LEGN

$16.25-5.67 (-25.87%) 3M

close as of 2026-11-18 · 24h delayed · vol 2.2M (0.9x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when LEGN's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 10 Nov 2026-16.0%
  2. 18 Jun 2026-16.7%
  3. 2 Jun 2026+42.2%
  4. 12 May 2026+10.5%
  5. 11 May 2026-9.0%

    Nothing announced by LEGN that day or the session before.

  6. 4 May 2026+12.3%
  7. 20 Apr 2026+18.4%
  8. 15 Apr 2026+9.8%
  9. 6 Mar 2026+6.9%
  10. 23 Feb 2026+9.0%

Share of unusual movement by asset

For each asset, the share of LEGN's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Ciltacabtagene autoleucel
events and moves
1529%
Other company news (earnings, financing, releases naming no asset)—32%
Sessions with no dated event—40%

Assets

(2 total)
2Total Assets
1Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 2 of 2 assets
Target & Modality
Approved
BCMACell therapy
Multiple Myeloma
Preclinical / Unstaged
FCRL5Cell therapy
Multiple Myeloma

Upcoming events

(5 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
February 2027 (1)
Ciltacabtagene autoleucelPhase 2Multiple Myeloma
Est. primary completion 2027-02-26 · NCT04133636 · CT.gov ↗
What to watch
August 2027 (1)
Ciltacabtagene autoleucelPhase 2Multiple Myeloma
Est. primary completion 2027-08-26 · NCT06550895 · CT.gov ↗
What to watch
2028 (1)
April 2028 (1)
Ciltacabtagene autoleucelPhase 2Multiple Myeloma
Est. primary completion 2028-04-12 · NCT07149857 · CT.gov ↗
What to watch
2029 (1)
February 2029 (1)
Ciltacabtagene autoleucelPhase 3Multiple Myeloma
Est. primary completion 2029-02-14 · NCT04923893 · CT.gov ↗
What to watch
2030 (1)
September 2030 (1)
Ciltacabtagene autoleucelPhase 2Multiple Myeloma
Est. primary completion 2030-09-02 · NCT06577025 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(3)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

10 October 2025ApprovalCiltacabtagene autoleucelFDA approves CARVYKTI label update with overall survival data
US, FDA · Source ↗
5 April 2024ApprovalCiltacabtagene autoleucelFDA approves CARVYKTI for earlier lines (CARTITUDE-4)
US, FDA · Janssen Biotech, Inc. · Source ↗
27 January 2023Topline resultCiltacabtagene autoleucelCARTITUDE-4 meets primary PFS endpoint
Legend Biotech · Source ↗

Financial reports

Quarterly & interim (7)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-Q3$11M$113M$279M$40M$29M operating cash flowreport ↗

Legend Biotech Corporation reported revenue of $10.5M, down 39.6% YoY, R&D spend of $113.15M, up 18.5% YoY, cash and equivalents of $278.89M, and a net loss of $39.69M for Q3 2025.

Figures only: this period's report disclosed no narrative text

View 6 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-Q2$35M$98M$267M$125M-$13M operating cash flowreport ↗
2025-Q1$9.4M$102M$442M$101M-$104M operating cash flowreport ↗
2024-Q3$17M$96M$459M$125M-$76M operating cash flowreport ↗
2024-Q2$93M$113M$201M$18M-$1.6M operating cash flowreport ↗
2024-Q1$16M$101M$898M$60M$16M operating cash flowreport ↗
2023-Q1—$85M$660M$112M-$139M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$1.0B$415M$902M$74M-$100M operating cash flowreport ↗
View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$145M$414M$287M$44M-$144M operating cash flowreport ↗
2023-FY$35M$382M$1.3B$130M-$393M operating cash flowreport ↗
2022-FY$117M$336M$786M$112M-$201M operating cash flowreport ↗
2021-FY$90M$313M$689M$97M-$198M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 2 purchases ($183K), 5 sales ($567K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-13Salovey Peter · directorOpen-market purchase10,000$8.95$90KForm 4
2026-11-12Salovey Peter · directorOpen-market purchase10,000$9.38$94KForm 4
2026-09-29Sanders Corazon (Corsee) D. · directorOpen-market sale27,370$9.46$259KForm 4
2026-09-24Sanders Corazon (Corsee) D. · directorAward / grant20,986——Form 4
2026-09-24Ji Darren Xiaohui · directorAward / grant28,330——Form 4
2026-09-24Casey Patrick John · directorAward / grant20,986——Form 4
2026-09-24Mao Li · directorAward / grant20,986——Form 4
2026-09-24Heyman Tomas J. · directorAward / grant20,986——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 190 reporting institutions held 96.1M shares ($1.7B, 26.0% of shares outstanding).

#InstitutionSharesValue
1FMR LLC25,696,740$464.9M
2DEERFIELD MANAGEMENT COMPANY, L.P.7,687,638$139.1M
3SUVRETTA CAPITAL MANAGEMENT, LLC7,581,029$137.1M
4HHLR ADVISORS, LTD.5,984,550$108.3M
5WESTFIELD CAPITAL MANAGEMENT CO LP5,763,475$104.3M
6BlackRock, Inc.4,684,543$84.7M
7Point72 Asset Management, L.P.3,886,017$70.3M
8First Beijing Investment Ltd2,296,335$41.5M
9Artisan Partners Limited Partnership2,254,488$40.8M
10TWO SIGMA INVESTMENTS, LP1,890,396$34.2M
11Kynam Capital Management, LP1,576,295$28.5M
12STATE STREET CORP1,498,372$27.1M
13GOLDMAN SACHS GROUP INC1,464,112$26.5M
14Davern Capital Partners, LP1,314,748$23.8M
15Patient Square Capital LP990,000$17.9M